267 related articles for article (PubMed ID: 22492994)
1. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation.
Cook C; Gendron TF; Scheffel K; Carlomagno Y; Dunmore J; DeTure M; Petrucelli L
Hum Mol Genet; 2012 Jul; 21(13):2936-45. PubMed ID: 22492994
[TBL] [Abstract][Full Text] [Related]
2. Tau triage decisions mediated by the chaperone network.
Cook C; Petrucelli L
J Alzheimers Dis; 2013; 33 Suppl 1():S145-51. PubMed ID: 22596270
[TBL] [Abstract][Full Text] [Related]
3. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.
Dickey CA; Kamal A; Lundgren K; Klosak N; Bailey RM; Dunmore J; Ash P; Shoraka S; Zlatkovic J; Eckman CB; Patterson C; Dickson DW; Nahman NS; Hutton M; Burrows F; Petrucelli L
J Clin Invest; 2007 Mar; 117(3):648-58. PubMed ID: 17304350
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 6 interacts with the microtubule-associated protein tau.
Ding H; Dolan PJ; Johnson GV
J Neurochem; 2008 Sep; 106(5):2119-30. PubMed ID: 18636984
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
[TBL] [Abstract][Full Text] [Related]
8. Akt and CHIP coregulate tau degradation through coordinated interactions.
Dickey CA; Koren J; Zhang YJ; Xu YF; Jinwal UK; Birnbaum MJ; Monks B; Sun M; Cheng JQ; Patterson C; Bailey RM; Dunmore J; Soresh S; Leon C; Morgan D; Petrucelli L
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3622-7. PubMed ID: 18292230
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 mediates the acetylation of TRIM50.
Fusco C; Micale L; Augello B; Mandriani B; Pellico MT; De Nittis P; Calcagnì A; Monti M; Cozzolino F; Pucci P; Merla G
Cell Signal; 2014 Feb; 26(2):363-9. PubMed ID: 24308962
[TBL] [Abstract][Full Text] [Related]
10. Hsp multichaperone complex buffers pathologically modified Tau.
Moll A; Ramirez LM; Ninov M; Schwarz J; Urlaub H; Zweckstetter M
Nat Commun; 2022 Jun; 13(1):3668. PubMed ID: 35760815
[TBL] [Abstract][Full Text] [Related]
11. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
Kovacs JJ; Murphy PJ; Gaillard S; Zhao X; Wu JT; Nicchitta CV; Yoshida M; Toft DO; Pratt WB; Yao TP
Mol Cell; 2005 May; 18(5):601-7. PubMed ID: 15916966
[TBL] [Abstract][Full Text] [Related]
13. Protopine promotes the proteasomal degradation of pathological tau in Alzheimer's disease models via HDAC6 inhibition.
Sreenivasmurthy SG; Iyaswamy A; Krishnamoorthi S; Senapati S; Malampati S; Zhu Z; Su CF; Liu J; Guan XJ; Tong BC; Cheung KH; Tan JQ; Lu JH; Durairajan SSK; Song JX; Li M
Phytomedicine; 2022 Feb; 96():153887. PubMed ID: 34936968
[TBL] [Abstract][Full Text] [Related]
14. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
[TBL] [Abstract][Full Text] [Related]
15. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
16. Interplay between HDAC6 and its interacting partners: essential roles in the aggresome-autophagy pathway and neurodegenerative diseases.
Yan J
DNA Cell Biol; 2014 Sep; 33(9):567-80. PubMed ID: 24932665
[TBL] [Abstract][Full Text] [Related]
17. Tau--an inhibitor of deacetylase HDAC6 function.
Perez M; Santa-Maria I; Gomez de Barreda E; Zhu X; Cuadros R; Cabrero JR; Sanchez-Madrid F; Dawson HN; Vitek MP; Perry G; Smith MA; Avila J
J Neurochem; 2009 Jun; 109(6):1756-66. PubMed ID: 19457097
[TBL] [Abstract][Full Text] [Related]
18. In vivo evidence of CHIP up-regulation attenuating tau aggregation.
Sahara N; Murayama M; Mizoroki T; Urushitani M; Imai Y; Takahashi R; Murata S; Tanaka K; Takashima A
J Neurochem; 2005 Sep; 94(5):1254-63. PubMed ID: 16111477
[TBL] [Abstract][Full Text] [Related]
19. CHIP-ping away at tau.
Goryunov D; Liem RK
J Clin Invest; 2007 Mar; 117(3):590-2. PubMed ID: 17332887
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.
Xiong Y; Zhao K; Wu J; Xu Z; Jin S; Zhang YQ
Proc Natl Acad Sci U S A; 2013 Mar; 110(12):4604-9. PubMed ID: 23487739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
